Article info
Student essay
Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement
- Correspondence to Riccardo Miceli McMillan, Doctorate of Medicine: Student, The University of Queensland Faculty of Medicine, Brisbane, QLD 4072, Australia; riccardo.micelimcmillan{at}uqconnect.edu.au
Citation
Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement
Publication history
- Received June 22, 2020
- Revised October 8, 2020
- Accepted October 15, 2020
- First published November 4, 2020.
Online issue publication
September 22, 2021
Article Versions
- Previous version (4 November 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Ethics and ego dissolution: the case of psilocybin
- Supple bodies, healthy minds: yoga, psychedelics and American mental health
- Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?
- PSYCHEDELIC DRUGS, MAGICAL THINKING AND PSYCHOSIS
- With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis
- Psychedelic crossings: American mental health and LSD in the 1970s
- The Well-Being Index WHO-5: hedonistic foundation and practical limitations
- Research abuses against people of colour and other vulnerable groups in early psychedelic research
- What is it to do good medical ethics? On the concepts of ‘good’ and ‘goodness’ in medical ethics
- Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)